Lucid Diagnostics
LUCDLucid Diagnostics is a commercial-stage medical technology company specializing in the early detection and prevention of esophageal cancer.
Earnings
Next report
Nov 12, 2026 (In 1 week)Valuation & ratios
Competitors
By market cap
By revenue growth
By net margin
Profile
Lucid Diagnostics is a commercial-stage medical technology company specializing in the early detection and prevention of esophageal cancer. The company provides a non-invasive diagnostic platform designed to identify esophageal precancer in patients with chronic heartburn and gastroesophageal reflux disease (GERD). Its core value proposition is offering a patient-friendly, office-based alternative to traditional invasive endoscopy for widespread screening.
Lucid Diagnostics holds a first-mover advantage with the only commercially available non-invasive esophageal cell collection and DNA testing system endorsed by major clinical guidelines as an alternative to endoscopy.
FAQ
- What is Lucid Diagnostics's market cap?
- Lucid Diagnostics (LUCD) has a market capitalization of $82.5M and trades on NASDAQ.
- What is Lucid Diagnostics's revenue and profitability?
- Lucid Diagnostics generated $5.4M in trailing twelve-month revenue with a net loss of $52.3M, representing a net margin of -959.8%. Gross margin stands at -57.3%. The latest reported period is Q2 2026.
- Who are Lucid Diagnostics's competitors?
- Lucid Diagnostics's key competitors include Guardant Health, Castle Biosciences, Inc. Common Stock, PAVmed Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does Lucid Diagnostics partner with?
- Lucid Diagnostics's notable partners include Case Western Reserve University, UpScript, LLC, Coastline International, and others.
- What subsidiaries does Lucid Diagnostics have?
- Lucid Diagnostics's subsidiaries include LucidDx Labs Inc., CapNostics, LLC.
- Where is Lucid Diagnostics headquartered?
- Lucid Diagnostics is headquartered in United States of America and employs approximately 70 people. It has been publicly traded since 2021.
